Gilead Sciences offers innovative drugs and boasts a 45,000% return since IPO, highlighting substantial growth. Investing in Gilead is accessible via brokerage accounts, using simple steps to buy ...

While the broader market has struggled with the S&P 500 down 2.4% since December 2024, Gilead Sciences has surged ahead as its stock price has climbed by 21% to $111.47 per share. This performance may ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. Featuring daily updates ...

Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in ...

Last week, biotech bigwig Gilead Sciences, Inc. GILD reported lower-than-expected first-quarter 2025 results. Adjusted earnings per share (EPS) of $1.81 missed the Zacks Consensus Estimate by a penny.

Generally speaking, I’m not a big fan of discussing biopharmaceutical firms such as Gilead Sciences (NASDAQ:GILD). While the sector is intriguing and offers bountiful opportunities, it’s also replete ...

During market trading hours on Wednesday, the U.S. Food and Drug Administration (FDA) approved Gilead Sciences, Inc.’s (NASDAQ:GILD) Yeztugo (lenacapavir) as pre-exposure prophylaxis (PrEP) to reduce ...